| ORIGINAL ARTICLES |
|
|
|
|
|
Indole alkaloids of Alstonia scholaris (L.) R. Br. alleviated nonalcoholic fatty liver disease in mice fed with high-fat diet |
| Shui-Fen Sun1,2, Hui-Jie Zhong1,2,3, Yun-Li Zhao4, Xiu-Ying Ma1, Jin-Bo Luo1, Ling Zhu1, Yu-Ting Zhang1, Wen-Xue Wang1,2, Xiao-Dong Luo4, Jia-Wei Geng1,2,3 |
1 Department of Infectious Disease and Hepatic Disease, First People’s Hospital of Yunnan Province, Afliated Hospital of Kunming University of Science and Technology, Kunming 650032, Yunnan, China;
2 School of Medicine, Kunming University of Science and Technology, Kunming 650500, Yunnan, China;
3 Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, Yunnan, China;
4 State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650201, People’s Republic of China |
|
|
|
|
Abstract Alstonia scholaris (L.) R. Br (Apocynaceae) is a well-documented medicinal plant for treating respiratory diseases, liver diseases and diabetes traditionally. The current study aimed to investigate the effects of TA on non-alcoholic fatty liver disease (NAFLD). A NAFLD model was established using mice fed a high-fat diet (HFD) and administered with TA (7.5, 15 and 30 mg/kg) orally for 6 weeks. The biochemical parameters, expressions of lipid metabolism-related genes or proteins were analyzed. Furthermore, histopathological examinations were evaluated with Hematoxylin–Eosin and MASSON staining. TA treatment significantly decreased the bodyweight of HFD mice. The concentrations of lowdensity lipoprotein (LDL), triglyceride (TG), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were also decreased significantly in TA-treated mice group, accompanied by an increase in high-density lipoprotein (HDL). Furthermore, TA alleviated hepatic steatosis injury and lipid droplet accumulation of liver tissues. The liver mRNA levels involved in hepatic lipid synthesis such as sterol regulatory element-binding protein 1C (SREBP-1C), regulators of liver X receptor α (LXRα), peroxisome proliferator activated receptor (PPAR)γ, acetyl-CoA carboxylase (ACC1) and stearyl coenzyme A dehydrogenase-1 (SCD1), were markedly decreased, while the expressions involved in the regulation of fatty acid oxidation, PPARα, carnitine palmitoyl transterase 1 (CPT1A), and acyl coenzyme A oxidase 1 (ACOX1) were increased in TA-treated mice. TA might attenuate NAFLD by regulating hepatic lipogenesis and fatty acid oxidation.
|
| Keywords
Hepatic disease
Hepatic lipogenesis
Fatty acid oxidation
|
| Fund:The authors are grateful to Yunnan Province Innovation Team of Intestinal Microecology-Related Disease Research and Technological Transformation (202005AE160010), National Natural Science Foundation of China (81860437), Prominent Physician Project of Yunnan province (YNWR-MY-2019-072), Yunnan Major Science and Technology Project (2019ZF004) and Digestive Endoscopy Medical Center (2019LCZXKF-XH05) for fnancial support. |
|
Corresponding Authors:
Wen-Xue Wang, E-mail:wenxue_wang@163.com;Xiao-Dong Luo, E-mail:xdluo@mail.kib.ac.cn;Jia-Wei Geng, E-mail:Jiawei_Geng@kmust.edu.cn
E-mail: wenxue_wang@163.com;xdluo@mail.kib.ac.cn;Jiawei_Geng@kmust.edu.cn
|
|
Issue Date: 26 April 2022
|
|
|
1.Michelotti GA, Machado MV, Diehl AM.NAFLD, NASH and liver cancer.Nat Rev Gastroenterol Hepatol.2013;10:656–65.
2.Angulo P.Medical progress-Nonalcoholic fatty liver disease.N Engl J Med.2002;346:1221–31.
3.Asgharpour A, Cazanave SC, Pacana T, Seneshaw M, Vincent R, Banini BA, Kumar DP, Daita K, Min H-K, Mirshahi F, Bedossa P, Sun X, Hoshida Y, Koduru SV, Contaifer D Jr, Warncke O, Wijesinghe DS, Sanyal AJ.A dietinduced animal model of non-alcoholic fatty liver disease and hepatocellular cancer.J Hepatol.2016;65:579–88.
4.Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M.Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes.Hepatology.2016;64:73–84.
5.Cohen P, Miyazaki M, Socci ND, Hagge-Greenberg A, Liedtke W, Soukas AA, Sharma R, Hudgins LC, Ntambi JM, Friedman JM.Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss.Science.2002;297:240–3.
6.Meex RCR, Watt MJ.Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance.Nat Rev Endocrinol.2017;13:508–20.
7.Romero-Gomez M, Zelber-Sagi S, Trenell M.Treatment of NAFLD with diet, physical activity and exercise.J Hepatology.2017;67:829–46.
8.Kwo PY, Cohen SM, Lim JK.ACG clinical guideline: evaluation of abnormal liver chemistries.Am J Gastroenterol.2017;112:18–35.
9.Hodson L, Gunn PJ.The regulation of hepatic fatty acid synthesis and partitioning: the effect of nutritional state.Nat Rev Endocrinol.2019;15:689–700.
10.Huang K, Du M, Tan X, Yang L, Li X, Jiang Y, Wang C, Zhang F, Zhu F, Cheng M, Yang Q, Yu L, Wang L, Huang D, Huang K.PARP1-mediated PPAR alpha poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease.J Hepatol.2017;66:962–77.
11.Ratziu V, Charlotte F, Bernhardt C, Giral P, Halbron M, LeNaour G, Hartmann-Heurtier A, Bruckert E, Poynard T, Grp LS.Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial.Hepatology.2010;51:445–53.
12.Kwon YM, Oh SW, Hwang SS, Lee CM, Kwon H, Chung GE.Association of nonalcoholic fatty liver disease with components of metabolic syndrome according to body mass index in korean adults.Am J Gastroenterol.2012;107:1852–8.
13.Feng Q, Gou XJ, Meng SX, Huang C, Zhang YQ, Tang YJ, Wang WJ, Xu L, Peng JH, Hu YY.Qushi Huayu Decoction Inhibits Hepatic Lipid Accumulation by Activating AMP-Activated Protein Kinase In Vivo and In Vitro.Evid Based Complement Alternat Med.2013;2013:1.
14.Ahmad FB, Holdsworth DK.Medicinal plants of Sabah, East Malaysia-Part I.Pharm Biol.2003;41:340–6.
15.Compiling Group of Yunnan Traditional Chinese Medicine.Medicine.Kunming: Yunnan Traditional Chinese Medicinal Plant.Yunnan People’s Press; 1977.
16.Cai XH, Du ZZ, Luo XD.Unique monoterpenoid indole alkaloids from Alstonia scholaris.Org Lett.2007;9:1817–20.
17.Cai XH, Tan QG, Liu YP, Feng T, Du ZZ, Li WQ, Luo XD.A cage-monoterpene indole alkaloid from Alstonia scholaris.Org Lett.2008;10:577–80.
18.Cai XH, Liu YP, Feng T, Luo XD.Picrinine-type Alkaloids from the Leaves of Alstonia scholaris.Chin J Nat Med.2008;6:20–2.
19.Cai XH, Shang JH, Feng T, Luo XD.Novel Alkaloids from Alstonia scholaris.Z Naturforsch B.2010;65:1164–8.
20.Cai XH, Bao MF, Zhang Y, Zeng CX, Liu YP, Luo XD.A New Type of Monoterpenoid Indole Alkaloid Precursor from Alstonia rostrata.Org Lett.2011;13:3568–71.
21.Chen YY, Yang J, Yang XW, Khan A, Liu L, Wang B, Zhao YL, Liu YP, Ding ZT, Luo XD.Alstorisine A, a nor-monoterpenoid indole alkaloid from cecidogenous leaves of Alstonia scholaris.Tetrahedron Lett.2016;57:1754–7.
22.Du GS, Cai XH, Shang JH, Luo XD.Non-alkaline constituents from the leaf of Alstonia scholaris.Chin J Nat Med.2007;5:259–62.
23.Du GS, Shang JH, Cai XH, Luo XD.Antitussive constituents from roots of Alstonia scholaris (Apocynaceae).Acta Bot Yunnanica.2007;29:366–365.
24.Feng T, Cai XL, Du ZZ, Luo XD.Iridoids from the Bark of Alstonia scholaris.Helv Chim Acta.2008;91:2247–51.
25.Feng T, Cai XH, Zhao PJ, Du ZZ, Li WQ, Luo XD.Monoterpenoid Indole Alkaloids from the Bark of Alstonia scholaris.Planta Med.2009;75:1537–41.
26.Liu L, Chen YY, Qin XJ, Wang B, Jin Q, Liu YP, Luo XD.Antibacterial monoterpenoid indole alkaloids from Alstonia scholaris cultivated in temperate zone.Fitoterapia.2015;105:160–4.
27.Pan ZQ, Qin XJ, Liu YP, Wu T, Luo XD, Xie CF.Alstoscholarisines H-J, Indole Alkaloids from Alstonia scholaris: Structural Evaluation and Bioinspired Synthesis of Alstoscholarisine H.Org Lett.2016;18:654–7.
28.Qin XJ, Zhao YL, Lunga PK, Yang XW, Song CW, Cheng GG, Liu L, Chen YY, Liu YP, Luo XD.Indole alkaloids with antibacterial activity from aqueous fraction of Alstonia scholaris.Tetrahedron.2015;71:4372–8.
29.Qin XJ, Zhao YL, Song CW, Wang B, Chen YY, Liu L, Li Q, Li D, Liu YP, Luo XD.Monoterpenoid Indole Alkaloids from Inadequately Dried Leaves of Alstonia scholaris.Nat Prod Bioprospect.2015;5:185–93.
30.Wei X, Dai Z, Yang J, Khan A, Yu HF, Zhao YL, Wang YF, Liu YP, Yang ZF, Huang WY, Wang XH, Zhao XD, Luo XD.Unprecedented sugar bridged bisindoles selective inhibiting glioma stem cells.Bioorg Med Chem.2018;26:1776–83.
31.Wei X, Qin XJ, Jin Q, Yu HF, Ding CF, Khan A, Liu YP, Xia CF, Luo XD.Indole alkaloids with self-activated sp(2) C-H bond from Alstonia scholaris.Tetrahedron Lett.2020;61:1.
32.Y.Xu, T.Feng, X.H.Cai, X.D.Luo.A New C13-Norisoprenoid from Leaves of Alstonia scholaris.Chin J Nat Med; 2009.
33.Yang XW, Qin XJ, Zhao YL, Lunga PK, Li XN, Jiang SZ, Cheng GG, Liu YP, Luo XD.Alstolactines A-C, novel monoterpenoid indole alkaloids from Alstonia scholaris.Tetrahedron Lett.2014;55:4593–6.
34.Yang XW, Luo XD, Lunga PK, Zhao YL, Qin XJ, Chen YY, Liu L, Li XN, Liu YP.Scholarisines H-O, novel indole alkaloid derivatives from long-term stored Alstonia scholaris.Tetrahedron.2015;71:3694–8.
35.Yang XW, Song CW, Zhang Y, Khan A, Jiang LP, Chen YB, Liu YP, Luo XD.Alstoscholarisines F and G, two unusual monoterpenoid indole alkaloids from the leaves of Alstonia scholaris.Tetrahedron Lett.2015;56:6715–8.
36.Yu HF, Huang WY, Ding CF, Wei X, Zhang LC, Qin XJ, Ma HX, Yang ZF, Liu YP, Zhang RP, Wang XH, Luo XD.Cage-like monoterpenoid indole alkaloids with antimicrobial activity from Alstonia scholaris.Tetrahedron Lett.2018;59:2975–8.
37.Zhang ZY, Luo XD, Li S.Comparative genetic and chemical profiling performed on Alstonia scholaris in China and its implications to standardization of Traditional Chinese Medicine.J Med Plants Res.2014;8:301–6.
38.Hou YY, Cao XL, Dong LY, Wang LQ, Cheng BF, Shi Q, Luo XD, Bai G.Bioactivity-based liquid chromatography-coupled electrospray ionization tandem ion trap/time of flight mass spectrometry for beta(2)AR agonist identification in alkaloidal extract of Alstonia scholaris.J Chromatogr A.2012;1227:203–9.
39.Shang JH, Cai XH, Zhao YL, Feng T, Luo XD.Pharmacological evaluation of Alstonia scholaris: anti-tussive, anti-asthmatic and expectorant activities.J Ethnopharmacol.2010;129:293–8.
40.Yang KF, Zhao YL.Study on the lowest effective dose of Alstonia scholaris (L.) R.Br.for anti-tussive and anti-asthmatic effects in guinea pigs.Yunnan J Trad Chin Med Materia Medica.2013;34:2.
41.Zhao YL, Cao J, Shang JH, Liu YP, Khan A, Wang HS, Qian Y, Liu L, Ye M, Luo XD.Airways antiallergic effect and pharmacokinetics of alkaloids from Alstonia scholaris.Phytomedicine.2017;27:63–72.
42.Zhao YL, Shang JH, Pu SB, Wang HS, Wang B, Liu L, Liu YP, Shen HM, Luo XD.Effect of total alkaloids from Alstonia scholaris on airway inflammation in rats.J Ethnopharmacol.2016;178:258–65.
43.Zhao YL, Yang ZF, Shang JH, Huang WY, Wang B, Wei X, Khan A, Yuan ZW, Liu YP, Wang YF, Wang XH, Luo XD.Effects of indole alkaloids from leaf of Alstonia scholaris on post-infectious cough in mice.J Ethnopharmacol.2018;218:69–75.
44.Zhao YL, Yang XW, Wu BF, Shang JH, Liu YP, Zhi D, Luo XD.Anti-inflammatory effect of pomelo peel and its bioactive coumarins.J Agric Food Chem.2019;67:8810–8.
45.Zhou HX, Li RF, Wang YF, Shen LH, Cai LH, Weng YC, Zhang HR, Chen XX, Wu X, Chen RF, Jiang HM, Wang CY, Yang MR, Lu JG, Luo XD, Jiang ZH, Yang ZF.Total alkaloids from Alstonia scholaris inhibit influenza a virus replication and lung immunopathology by regulating the innate immune response.Phytomedicine.2020;77:1.
46.Zhao YL, Yang ZF, Wu BF, Shang JH, Liu YP, Wang XH, Luo XD.Indole alkaloids from leaves of Alstonia scholaris (L.) R.Br.protect against emphysema in mice.J Ethnopharmacol.2020;259:1.
47.Zhao YL, Gou ZP, Shang JH, Li WY, Kuang Y, Li MY, Luo XD.Anti-microbial Effects In Vitro and In Vivo of Alstonia scholaris.Nat Prod Bioprospect.2021;11:127–35.
48.Zhao YL, Pu SB, Qi Y, Wu BF, Shang JH, Liu YP, Hu D, Luo XD.Pharmacological effects of indole alkaloids from Alstonia scholaris (L.) R Br on pulmonary fibrosis in vivo.J Ethnopharmacol.2021;267:1.
49.Zhao YL, Su M, Shang JH, Wang X, Bao GL, Ma J, Sun QD, Yuan F, Wang JK, Luo XD.Acute and Sub-chronic Toxicity of Indole Alkaloids Extract from Leaves of Alstonia scholaris (L) R Br in Beagle Dogs.Nat Prod Bioprospect.2020;10:209–20.
50.Zhao YL, Su M, Shang JH, Wang X, Bao GL, Ma J, Sun QD, Yuan F, Wang JK, Luo XD.Genotoxicity and safety pharmacology studies of indole alkaloids extract from leaves of Alstonia scholaris (L) R Br.Nat Prod Bioprospect.2020;10:119–29.
51.Zhao YL, Su M, Shang JH, Wang X, Njateng GSS, Bao GL, Ma J, Sun QD, Yuan F, Wang JK, Luo XD.Acute and chronic toxicity of indole alkaloids from Leaves of Alstonia scholaris (L) R Br in Mice and Rats.Nat Prod Bioprospect.2020;10:77–88.
52.Gou ZP, Zhao YL, Zou LL, Wang Y, Shu SQ, Zhu XH, Zheng L, Shen Q, Luo Z, Miao J, Wang YS, Luo XD, Feng P.The safety and tolerability of alkaloids from Alstonia scholaris leaves in healthy Chinese volunteers: a singlecentre, randomized, double-blind, placebo-controlled phase I clinical trial.Pharm Biol.2021;59:484–93.
53.Li R, Zi MJ, Gou ZP, Zhao YL, Zhang WT, Lu F, Cao WY, Zhao YP, Li QN, Zhao Y, Wang SG, Gao HY, Sun MY, Luo XD, Xiong ZL, Gao R.Pharmacokinetics and safety evaluation in healthy Chinese volunteers of alkaloids from leaf of Alstonia scholaris: A multiple doses phase I clinical trial.Phytomedicine.2019;61:1.
54.Cao J, Shen HM, Wang Q, Qian Y, Guo HC, Li K, Qiao X, Guo DA, Luo XD, Ye M.Characterization of chemical constituents and rats metabolites of an alkaloidal extract of Alstonia scholaris leaves by liquid chromatography coupled with mass spectrometry.J Chromatogr B.2016;1026:43–55.
55.Hou YY, Cao XL, Wang LQ, Cheng BF, Dong LY, Luo X, Bai G, Gao WY.Microfractionation bioactivity-based ultra performance liquid chromatography/ quadrupole time-of-flight mass spectrometry for the identification of nuclear factor-kappa B inhibitors and beta(2) adrenergic receptor agonists in an alkaloidal extract of the folk herb Alstonia scholaris.J Chromatogr B.2012;908:98–104.
56.Shang JH, Cai XH, Feng T, Zhao YL, Wang JK, Zhang LY, Yan M, Luo XD.Pharmacological evaluation of Alstonia scholaris: anti-inflammatory and analgesic effects.J Ethnopharmacol.2010;129:174–81.
57.Joshi, S.G, Medicinal plants: Family Apiaceae.In Oxford and IBH publishing Co.Pvt.Ltd: New Delhi, 2000; pp 40–41.
58.P.K.Warrier, V.P.K.Nambiar, C.Ramankutty, Indian medicinal plants.Orient Longman Ltd., Hyderabad, India: 1996; Vol.5.
59.Sharma R, Sharma HK.Ethnomedicines of Sonapur, Kamrup District Assam.Indian J Trad Knowl.2010;9:163–5.
60.de Sa PM, Richard AJ, Hang H, Stephens JM.Transcriptional regulation of adipogenesis.Compr Physiol.2017;7:635–74.
61.Shimano H, Sato R.SREBP-regulated lipid metabolism: convergent physiology— divergent pathophysiology.Nat Rev Endocrinol.2017;13:710–30.
62.Ann JY, Eo H, Lim Y.Mulberry leaves (Morus alba L.) ameliorate obesityinduced hepatic lipogenesis, fibrosis, and oxidative stress in high-fat diet-fed mice.Genes Nutr.2015;10:1.
63.Du W, Zhang L, Brett-Morris A, Aguila B, Kerner J, Hoppel CL, Puchowicz M, Serra D, Herrero L, Rini BI, Campbell S, Welford SM.HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolism.Nat Commun.2017;8:1.
64.Francque S, Verrijken A, Caron S, Prawitt J, Paumelle R, Derudas B, Lefebvre P, Taskinen M-R, Van Hul W, Mertens I, Hubens G, Van Marck E, Michielsen P, Van Gaal L, Staels B.PPAR alpha gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis.J Hepatol.2015;63:164–73.
65.Li M, Ye T, Wang XX, Li X, Qiang O, Yu T, Tang CW, Liu R.Effect of Octreotide on Hepatic Steatosis in Diet-Induced Obesity in Rats.PLoS ONE.2016;11:1.
66.Hebbard L, George J.Animal models of nonalcoholic fatty liver disease.Nat Rev Gastroenterol Hepatol.2011;8:34–44.
67.Liou CJ, Lee YK, Ting NC, Chen YL, Shen SC, Wu SJ, Huang WC.Protective effects of licochalcone a ameliorates obesity and non-alcoholic fatty liver disease via promotion of the Sirt-1/AMPK pathway in mice fed a high-fat diet.Cells.2019;8:1.
68.Moon Y-A, Liang GS, Xie XF, Frank-Kamenetsky M, Fitzgerald K, Koteliansky V, Brown MS, Goldstein JL, Horton JD.The Scap/SREBP pathway is essential for developing diabetic fatty liver and carbohydrate-induced hypertriglyceridemia in animals.Cell Metab.2012;15:240–6.
69.Tilg H, Moschen AR.Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis.Hepatology.2010;52:1836–46.
70.Ren LY, Sun DM, Zhou X, Yang YF, Huang XQ, Li YX, Wang CX, Li YH.Chronic treatment with the modified Longdan Xiegan Tang attenuates olanzapine-induced fatty liver in rats by regulating hepatic de novo lipogenesis and fatty acid beta-oxidation-associated gene expression mediated by SREBP-1c PPAR-alpha and AMPK-alpha.J Ethnopharmacol.2019;232:176–87.
71.Sugden MC, Bulmer K, Gibbons GF, Knight BL, Holness MJ.Peroxisomeproliferator-activated receptor-alpha (PPAR alpha) deficiency leads to dysregulation of hepatic lipid and carbohydrate metabolism by fatty acids and insulin.Biochem J.2002;364:361–8.
72.Loria P, Marchesini G, Nascimbeni F, Ballestri S, Maurantonio M, Carubbi F, Ratziu V, Lonardo A.Cardiovascular risk, lipidemic phenotype and steatosis.A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology.Atherosclerosis.2014;232:99–109.
73.Narwal V, Deswal R, Batra B, Kalra V, Hooda R, Sharma M, Rana JS.Cholesterol biosensors: a review.Steroids.2019;143:6–17. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
